Publication | Open Access

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Platinum-based TherapyDisease ProgressionMedicineClinical TrialsBronchial NeoplasmImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung CancerPhase 3Health Sciences